News

Conference Coverage

Adjuvant Pembrolizumab Improved Disease-Free Survival Among Patients With Muscle-Invasive Bladder Cancer

01/26/2024

Stephanie Holland

Interim DFS/OS results from the phase 3 AMBASSADOR Alliance AO31501 study demonstrated adjuvant pembrolizumab improved DFS among patients with high-risk muscle-invasive urothelial carcinoma.

Interim DFS/OS results from the...

01/26/2024

Oncology

Conference Coverage

Oral APL-1202 Plus Tislelizumab Shows Promise in Neoadjuvant Setting Among Patients With Muscle-Invasive Bladder Cancer

01/26/2024

Allison Casey

According to results from a phase 1/2 study, the combination of oral APL-1202 and tislelizumab in the neoadjuvant setting showed promising activity and safety among patients with muscle-invasive bladder cancer.

According to results from a...

01/26/2024

Oncology

FDA Approval

FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations

01/20/2024

Stephanie Holland

Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.

Based on results from cohort 1...

01/20/2024

Oncology

News

Tremelimumab Shows Potential Among Patients With PD-1/PD-L1–Resistant Metastatic Urothelial Cancer

01/12/2024

Allison Casey

According to a phase 2 trial, a high dose of tremelimumab showed modest activity and similar toxicity as previously reported among patients with PD-1/PD-L1–resistant metastatic urothelial cancer.

According to a phase 2 trial, a...

01/12/2024

Oncology

News

Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma

01/08/2024

Allison Casey

According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.

According to a retrospective...

01/08/2024

Oncology

News

No Survival Benefit With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Patients With Muscle-Invasive Bladder Cancer

01/05/2024

Allison Casey

According to 5-year data from the VESPER trial, dd-MVAC did not improve the overall survival among patients with muscle-invasive bladder cancer when compared with gemcitabine and cisplatin.

According to 5-year data from...

01/05/2024

Oncology

News

Pemigatinib Effective, Safe Among Patients With Unresectable or Metastatic Urothelial Carcinoma With FGFR3 Genetic Alterations

12/19/2023

Allison Casey

Final results from the phase 2 FIGHT-201 trial found pemigatinib demonstrated clinical activity and tolerable safety among patients with unresectable or metastatic urothelial carcinoma with FGFR3 genetic alterations.

Final results from the phase 2...

12/19/2023

Oncology

News

Erdafitinib Prolonged Overall Survival Among Patients With FGFR-Altered Metastatic Urothelial Carcinoma Treated With Checkpoint Inhibitors

12/01/2023

Allison Casey

According to the phase 3 THOR trial, erdafitinib prolonged overall survival among patients with FGFR-altered metastatic urothelial carcinoma who had previously received treatment with anti–PD-1/L1 agents, compared with chemotherapy.

According to the phase 3 THOR...

12/01/2023

Oncology

News

Disitamab Vedotin Shows Promise Among Patients With HER2-Positive Urothelial Carcinoma

11/30/2023

Allison Casey

According to an analysis of data from 2 phase 2 studies, disitamab vedotin showed promising efficacy with a tolerable safety profile among patients with previously treated, HER2-positive locally advanced/metastatic urothelial carcinoma.

According to an analysis of data...

11/30/2023

Oncology

News

Nivolumab Plus Gemcitabine-Cisplatin Improved Survival Outcomes Among Patients With Advanced Urothelial Carcinoma

11/30/2023

Allison Casey

According to results from the phase 3 CheckMate901 trial, nivolumab plus gemcitabine-cisplatin improved the overall survival and progression-free survival among patients with previously untreated advanced urothelial carcinoma, compared with...

According to results from the...

11/30/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology